Related Experiment Video

Updated: Jul 12, 2026

Primed Mycobacterial Uveitis (PMU) as a Model for Post-Infectious Uveitis
10:33

Primed Mycobacterial Uveitis (PMU) as a Model for Post-Infectious Uveitis

Published on: December 17, 2021

Use of tumor necrosis factor inhibitors in uveitis

C Egla Rabinovich1

  • 1Division of Pediatric Rheumatology, Duke University Medical Center, Durham, North Carolina 27710, USA. rabin001@mc.duke.edu

Current Opinion in Rheumatology
|September 1, 2007
PubMed

Insights

Tumor necrosis factor-alpha (TNF-α) blockers are increasingly used for chronic pediatric uveitis. Evidence suggests TNF-α blockade is effective for refractory cases, though more research is needed.

Area of Science:

  • Ophthalmology
  • Immunology
  • Pediatrics

Background:

  • Chronic pediatric uveitis often presents as idiopathic or associated with juvenile idiopathic arthritis, leading to significant visual impairment.
  • Standardization of disease and outcome measures has been a challenge in uveitis research.
  • Tumor necrosis factor-alpha (TNF-α) blocking agents represent a developing therapeutic option.

Purpose of the Study:

  • To review the rationale and recent studies on using TNF-α blocking agents for chronic pediatric uveitis.
  • To highlight the efficacy and limitations of current therapeutic approaches.

Main Methods:

  • Review of retrospective case series and existing literature on TNF-α blockade in pediatric uveitis.
  • Consideration of consensus measures for uveitis assessment.

Main Results:

  • Data suggest TNF-α blockade is efficacious in treating refractory pediatric uveitis.
  • Agents directly binding TNF-α membrane receptors may offer superior efficacy.
  • Retrospective study designs limit definitive conclusions.

Conclusions:

  • TNF-α blocking agents are crucial in managing chronic pediatric uveitis.
  • Further prospective, comparative studies are essential to optimize treatment regimens and assess long-term outcomes.
Abstract

More Related Videos

Experimental Autoimmune Uveitis: An Intraocular Inflammatory Mouse Model07:40

Experimental Autoimmune Uveitis: An Intraocular Inflammatory Mouse Model

Published on: January 12, 2022

Determination of the Relative Potency of an Anti-TNF Monoclonal Antibody (mAb) by Neutralizing TNF Using an In Vitro Bioanalytical Method16:07

Determination of the Relative Potency of an Anti-TNF Monoclonal Antibody (mAb) by Neutralizing TNF Using an In Vitro Bioanalytical Method

Published on: September 16, 2017

Related Concept Videos

Drugs for Treatment of Crohn's Disease in IBD Using Biologic Agents: Anti-TNF01:24

Drugs for Treatment of Crohn's Disease in IBD Using Biologic Agents: Anti-TNF

Tumor Necrosis Factor (TNF), a proinflammatory cytokine, contributes significantly to the inflammation seen in Crohn's disease. It exists as soluble TNF and membrane-bound TNF, with actions mediated through TNF receptors (TNFR). TNFR activation leads to the release of proinflammatory cytokines, T-cell activation, collagen production, and leukocyte migration, all contributing to inflammation in Crohn's disease. Anti-TNF monoclonal antibodies, namely infliximab (Remicade), adalimumab (Humira),...
Tumor Immunotherapy01:27

Tumor Immunotherapy

Immunotherapy is a treatment that boosts or manipulates the immune system to fight diseases, including cancer. For instance, by stimulating an immune response through vaccinations against viruses that cause cancers, like hepatitis B virus and human papillomavirus, these diseases can be prevented. Nonetheless, some cancer cells can avoid the immune system due to their rapid mutation and division. The immune response to many cancers involves three phases: elimination, equilibrium, and escape.
Inflammatory Bowel Disease IV: Pharmacological Management01:29

Inflammatory Bowel Disease IV: Pharmacological Management

Upon diagnosis, managing Inflammatory Bowel Disease (IBD) involves addressing several crucial aspects. The primary goals include resting the bowel, correcting malnutrition, and providing symptomatic relief. Resting the bowel may consist of medications to reduce inflammation and promote healing. Correcting malnutrition is essential, often requiring dietary adjustments and nutritional supplements. Symptomatic relief aims to ease pain, diarrhea, and other discomforts in IBD.
Pharmacologic...
Drugs for Treatment of Crohn's Disease in IBD Using Immunomodulatory Agents01:29

Drugs for Treatment of Crohn's Disease in IBD Using Immunomodulatory Agents

Crohn's disease is an inflammatory bowel disorder marked by chronic inflammation of the GI tract. Various treatment strategies for Crohn's disease are employed, such as immunomodulatory agents, glucocorticoids, and biologics or anti-TNF therapy. Azathioprine (Imuran), a commonly used immunomodulatory drug for Crohn's disease, is converted in the body to mercaptopurine, which inhibits purine biosynthesis and cell proliferation. Both are utilized in severe cases of Inflammatory Bowel Disease...
Open Angle Glaucoma: Treatment01:27

Open Angle Glaucoma: Treatment

In open-angle glaucoma, the iridocorneal angle remains open, but the trabecular meshwork becomes stiff, slowing down the outflow of aqueous humor. This causes a buildup of aqueous humor in the anterior chamber, leading to a sudden increase in intraocular pressure. The treatment for open-angle glaucoma focuses on reducing the elevated intraocular pressure by either decreasing the secretion of aqueous humor or increasing its outflow.
Drugs such as carbonic anhydrase inhibitors, α2- and...
Drugs for Treatment of Crohn's Disease in IBD Using Glucocorticoids01:21

Drugs for Treatment of Crohn's Disease in IBD Using Glucocorticoids

Glucocorticoids, a class of anti-inflammatory drugs, are pivotal in treating moderate to severe Crohn's disease by inducing remission. They exhibit their anti-inflammatory action by inhibiting the production of inflammatory cytokines such as tumor necrosis factor (TNF)-α, interleukin (IL)-1, and chemokines like IL-8. In addition, they reduce the expression of inflammatory cell adhesion molecules and inhibit gene transcription of nitric oxide synthase, phospholipase A2, cyclooxygenase-2 (COX-2),...